Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
Commentary|Articles|May 27, 2015
Patricia Carter on Sleep Disturbances in Patients and Caregivers
Author(s)Patricia Carter, PhD, RN, CNS
Patricia Carter, PhD, RN, CNS, associate professor, School of Nursing, The University of Texas at Austin, discusses a study looking at insomnia and sleep disturbances in patients and caregivers.
Advertisement
Patricia Carter, PhD, RN, CNS, associate professor, School of Nursing, The University of Texas at Austin, discusses a study looking at insomnia and sleep disturbances in patients and caregivers.
Advertisement
Related to this article
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.
At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.
At ASTRO 2026, Dr. Mishaal Munir details how nurse-led triage workflows and prompt symptom escalations improve care for breast cancer brain metastases.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Male Breast Cancer: Warning Signs, Biology, and Genetic Testing
2
Making Innovation Meaningful: Enabling Personalized Care in Multiple Myeloma
3
FDA Grants Traditional Approval to Pembrolizumab in TMB-H Solid Tumors
4
Sunvozertinib Now Available in US for Pretreated EGFR Exon 20+ NSCLC
5